Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation

Ascentage Pharma Group International (SEHK:6855) drew fresh market attention after presenting new ASCO 2026 data on olverembatinib in chronic myeloid leukemia and first clinical results for alrizomadlin in pediatric sarcomas.

See our latest analysis for Ascentage Pharma Group International.

The ASCO 2026 updates arrived as the stock posted a 3.93% 1 day share price gain to HK$34.9. That move sits against a year to date share price decline of 31.43% and a 1 year total shareholder return that is down 44.03%, following a 3 year total shareholder return of 57.21%.

If these oncology results have your attention, it could be a good moment to broaden your watchlist with other healthcare AI focused opportunities via the 133 healthcare AI stocks.

With ASCO data in hand, a share price that is down sharply over 1 year, and an intrinsic value estimate that sits below the current HK$34.9 level, investors now face a key question: is there a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 51.4% Undervalued

With Ascentage Pharma Group International last closing at HK$34.9 against a narrative fair value of HK$71.81, the current setup hinges on how investors view late stage oncology risk and reward.

The company remains fundamentally vulnerable due to its heavy reliance on a development-stage pipeline in highly competitive oncology segments, where clinical failure or regulatory delay, compounded by industry-wide scrutiny of trial design, could halt new product launches and trigger significant drops in projected revenue and net margins.

Read the complete narrative.

Curious how a stock that is still loss making can justify a much higher fair value? The narrative leans on strong revenue expansion, shifting margins and a rich future earnings multiple tied directly to key oncology assets.

Result: Fair Value of HK$71.81 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, stronger than expected Olverembatinib uptake in China or further Takeda milestone and royalty flows could quickly challenge the idea that the stock is undervalued.

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Another Angle on Valuation

The SWS DCF model suggests Ascentage Pharma Group International is trading below an estimated future cash flow value of HK$84.04 per share, which also points to an undervalued setup versus the current HK$34.9 level. With two methods pointing in the same direction, the key consideration is how comfortable you are with the underlying assumptions.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With sentiment split between downside risks and potential rewards, it may be useful to review the numbers for yourself and decide quickly where you stand with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop here, you might miss other stocks that fit what you are really after, so take a few minutes to widen your opportunity set.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com